search
Back to results

Riboflavin for Glutamate Reduction in Alcohol Withdrawal (RGRAW)

Primary Purpose

Alcohol Withdrawal, Nutrition Disorders, Alcohol Use Disorder

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Riboflavin
Placebo
Sponsored by
Oregon Health and Science University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol Withdrawal focused on measuring Glutamate, Riboflavin

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult veterans ages 18-65
  • Admitted to the inpatient psychiatric unit at the Portland VA
  • Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission
  • Placed on the CIWA-AR protocol
  • Willing to provide informed consent/HIPAA authorization and accept randomization
  • Willing to ingest three capsules/day
  • Willing to provide daily blood samples H) Fluent in English

Exclusion Criteria:

  • Known allergy to ingredients of riboflavin, capsules, or placebo ingredients
  • Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline
  • Unable to swallow capsules
  • Actively in withdrawal from substances other than alcohol
  • Unable to provide full informed consent/HIPAA authorization

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Riboflavin

    Placebo

    Arm Description

    Participants in this group will receive 100mg riboflavin TID during study participation.

    Participants in this group will receive inert placebo capsules TID during study participation.

    Outcomes

    Primary Outcome Measures

    Peripheral blood glutamate level at baseline
    measured using high performance liquid chromatography (HPLC)
    Peripheral blood glutamate level, day 2
    measured using high performance liquid chromatography (HPLC)
    Peripheral blood glutamate level, day 4
    measured using high performance liquid chromatography (HPLC)
    Peripheral blood glutamate level, day 6
    measured using high performance liquid chromatography (HPLC)
    Peripheral blood glutamate level, day 8
    measured using high performance liquid chromatography (HPLC)
    Peripheral blood glutamate level, day 10
    measured using high performance liquid chromatography (HPLC)

    Secondary Outcome Measures

    Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety

    Full Information

    First Posted
    January 13, 2020
    Last Updated
    September 27, 2021
    Sponsor
    Oregon Health and Science University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04232800
    Brief Title
    Riboflavin for Glutamate Reduction in Alcohol Withdrawal
    Acronym
    RGRAW
    Official Title
    Riboflavin for Glutamate Reduction in Alcohol Withdrawal
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 1, 2021 (Anticipated)
    Primary Completion Date
    August 25, 2022 (Anticipated)
    Study Completion Date
    October 25, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Oregon Health and Science University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In addition to receiving care as usual, they will be randomized to receive either 100mg TID riboflavin or an identically dosed placebo. The primary outcome measure will be blood glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol craving. The investigators hypothesize that those in the riboflavin group will have lower blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.
    Detailed Description
    General Investigational Plan Hypotheses: Aim 1: Measure the impact of daily oral riboflavin supplementation on blood Glu levels. Hypothesis 1: Patients receiving riboflavin will have significant reductions in blood Glu levels, as compared to placebo. Aim 2: Observe the impact of oral riboflavin on CIWA-AR scale scoring. Hypothesis 2: Riboflavin will significantly reduce the active group's CIWA-AR scores, and will result in fewer symptom triggered benzodiazepine doses, as compared to placebo. Plan: The proposed study would apply a recently identified method using vitamin B2 (riboflavin) to reduce excess brain Glu activity in veterans in acute alcohol withdrawal. This method of "glutamate scavenging", was identified in a 2018 as a way to reduce glutamate associated brain damage which typically occurs after stroke. When tested in human patients immediately following stroke, the intervention demonstrated efficacy through better structural and functional outcomes when compared to placebo. Improvements persisted at 3 months after the initial stroke, and were not associated with any known side effects. Administration of riboflavin quickly decreases Glu levels in both the blood and brain, as measured using chromatography and Magnetic Resonance Imaging (MRI), respectively. As riboflavin's Glu reducing properties have just been discovered, this method has only been applied to the treatment of stroke, and has yet to be studied outside of the field of neurology. Further, oral riboflavin has not been investigated as a method of glutamate reduction. The hyperglutamatergic state in patients with alcohol withdrawal provides one opportunity for such an investigation, one that may lead to future studies improving treatments of alcohol withdrawal. Chronic, as well as acute alcohol users have both elevated extracellular glutamate as well as changes to glutamate receptors and transporters. These changes appear play a role in the rewarding effects of alcohol, and contribute to the symptoms of withdrawal. A positive correlation exists between CSF levels of glutamate and the severity of alcohol dependence, and patients in acute withdrawal have measurably increased levels of glutamate in their peripheral blood. During early withdrawal, elevated glutamate levels have been observed in the hippocampus and anterior cingulate cortex, returning to normal 3 days after symptom resolution. Given this information, riboflavin may provide a safe, effective, and affordable intervention to normalize the hyperglutamatergic state associated with alcohol withdrawal. The proposed study would investigate this hypothesis in patients admitted to the inpatient psychiatry unit in acute alcohol withdrawal. Methods: Participants would be recruited on the inpatient psychiatry unit as they were admitted. The primary teams/on call residents would be asked to page a study member if a patient was admitted on the standard protocol for alcohol withdrawal: the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar). The study coordinator would consent the patient, and they would be randomized to either the placebo or riboflavin group. They would then receive TID oral dosing of either 100mg riboflavin or placebo, in addition to treatment as usual. The primary outcome would be daily blood glutamate levels, obtained with the normal morning labs. Secondary outcomes would CIWA scores, number of symptom-triggered benzodiazepines given, anxiety, and alcohol craving scores (using standardized measures).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Alcohol Withdrawal, Nutrition Disorders, Alcohol Use Disorder
    Keywords
    Glutamate, Riboflavin

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Model Description
    Participants will be randomized to receive either riboflavin or an identical inert placebo.
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Masking Description
    Treatment and placebo capsules will be identical, and will be identified with each participants unique randomization number provided by the VA pharmacy. This will ensure blinding until study completion. Neither participants nor any study or treatment team members will know the group allocation.
    Allocation
    Randomized
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Riboflavin
    Arm Type
    Experimental
    Arm Description
    Participants in this group will receive 100mg riboflavin TID during study participation.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Participants in this group will receive inert placebo capsules TID during study participation.
    Intervention Type
    Drug
    Intervention Name(s)
    Riboflavin
    Other Intervention Name(s)
    Vitamin B2
    Intervention Description
    The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    An inert, standard placebo in identical capsules to primary intervention.
    Primary Outcome Measure Information:
    Title
    Peripheral blood glutamate level at baseline
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Peripheral blood glutamate level, day 2
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on day 2 of the study
    Title
    Peripheral blood glutamate level, day 4
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on day 4 of the study
    Title
    Peripheral blood glutamate level, day 6
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on day 6 of the study
    Title
    Peripheral blood glutamate level, day 8
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on day 8 of the study
    Title
    Peripheral blood glutamate level, day 10
    Description
    measured using high performance liquid chromatography (HPLC)
    Time Frame
    Will occur on day 10 of the study
    Secondary Outcome Measure Information:
    Title
    Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
    Description
    The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
    Time Frame
    Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
    Title
    Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
    Description
    As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
    Time Frame
    Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
    Title
    Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale
    Description
    A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
    Time Frame
    Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
    Title
    Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)
    Description
    A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
    Time Frame
    Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
    Title
    Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day of enrollment in the study
    Title
    Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
    Title
    Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)
    Description
    A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
    Time Frame
    Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult veterans ages 18-65 Admitted to the inpatient psychiatric unit at the Portland VA Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission Placed on the CIWA-AR protocol Willing to provide informed consent/HIPAA authorization and accept randomization Willing to ingest three capsules/day Willing to provide daily blood samples H) Fluent in English Exclusion Criteria: Known allergy to ingredients of riboflavin, capsules, or placebo ingredients Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline Unable to swallow capsules Actively in withdrawal from substances other than alcohol Unable to provide full informed consent/HIPAA authorization
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Andrew J Hughes, MD
    Phone
    7014711543
    Email
    andrew.j.hughes.1@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Brandon Cornejo, MD, PhD
    Organizational Affiliation
    Oregon Health & Science University, Portland Veterans Health Administration
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Riboflavin for Glutamate Reduction in Alcohol Withdrawal

    We'll reach out to this number within 24 hrs